Daiichi Sankyo and Eli Lilly have announced that Effient (prasugrel), a new antiplatelet medicine, is now available in pharmacies across the US.
The FDA approved Effient tablets is for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes (ACS), who are managed with percutaneous coronary intervention.
Effient helps keep blood platelets from clumping together and developing a blockage in an artery. Taking Effient along with aspirin after PCI has been shown to reduce the chances of having a cardiac event such as a heart attack or stent-related blood clots in patients with ACS, said, the company.
Enrique Conterno, president of Lilly USA, said: We are excited about bringing Effient, to patients and their healthcare professionals, We will work closely with healthcare professionals to ensure they understand how Effient works and who the appropriate patients are to receive this innovative treatment.
Joe Pieroni, president and chief executive officer of Daiichi Sankyo, said: We recognize the need for practical patient support and education during this difficult time in patients’ lives, following a major cardiovascular event and possibly having a stent placed in an artery,We are dedicated to developing highly relevant, evidence-based programs to help patients recover as well as regain their health and confidence.